Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
09 07 2021
09 07 2021
Historique:
received:
12
07
2020
accepted:
29
06
2021
entrez:
10
7
2021
pubmed:
11
7
2021
medline:
9
11
2021
Statut:
epublish
Résumé
There are currently five programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors approved for the treatment of locally advanced or metastatic urothelial carcinoma (UC) of the bladder. For platinum-ineligible patients, testing of tumor specimens for PD-L1 expression is required. However, scoring of PD-L1 immunohistochemistry is complex due to different antibodies used, the requirement to score expression in different cellular compartments and intratumoral heterogeneity. It can also be difficult to obtain and test longitudinal tumor samples, which would be desirable to monitor treatment responses and tumor evolution under treatment-induced selective pressure. In the present proof-of concept study, we provide evidence that PD-L1 can be detected in the urine of patients with non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). Urine PD-L1 levels were significantly higher in NMIBC and MIBC patients when compared to patients with various non-malignant urological diseases. Further prospective and independent studies are required to assess the value of PD-L1 in the urine as a novel biomarker with potential for the early detection, prediction and therapeutic monitoring of patients with UC of the bladder.
Identifiants
pubmed: 34244564
doi: 10.1038/s41598-021-93754-z
pii: 10.1038/s41598-021-93754-z
pmc: PMC8270894
doi:
Substances chimiques
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
14244Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. The Author(s).
Références
Diseases. 2019 Jun 18;7(2):
pubmed: 31216733
Eur Urol. 2018 Nov;74(5):540-544
pubmed: 30033046
J Cancer. 2019 Jul 8;10(17):4038-4044
pubmed: 31417648
Ann Transl Med. 2019 Nov;7(22):690
pubmed: 31930091
Nat Med. 2014 Mar;20(3):272-82
pubmed: 24531377
Clin Cancer Res. 2020 Feb 15;26(4):882-891
pubmed: 31712383
J Immunother Cancer. 2017 Nov 21;5(1):94
pubmed: 29157296
Transplantation. 2010 Dec 27;90(12):1381-7
pubmed: 21079547
BJU Int. 2016 May;117(5):783-6
pubmed: 26435378
Cancer Immunol Immunother. 2019 Mar;68(3):421-432
pubmed: 30564891
Cancer. 2007 Apr 15;109(8):1499-505
pubmed: 17340590
Lancet. 2016 Dec 3;388(10061):2796-2810
pubmed: 27345655
Front Oncol. 2019 Nov 20;9:1270
pubmed: 31824850
Cancer Immunol Immunother. 2007 Aug;56(8):1173-82
pubmed: 17186290
Urol Oncol. 2020 Mar;38(3):77.e9-77.e15
pubmed: 31570249
Am J Cancer Res. 2019 Jun 01;9(6):1104-1117
pubmed: 31285945
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Ther Adv Med Oncol. 2018 Jul 30;10:1758835918788310
pubmed: 30083254
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593